Strongbridge Biopharma plc (SBBP) Reaches $6.75 After 9.00% Down Move; Key Technology (KTEC) Sentiment Is 2.33

January 26, 2018 - By Hazel Jackson

The stock of Strongbridge Biopharma plc (NASDAQ:SBBP) is a huge mover today! The stock decreased 6.25% or $0.45 during the last trading session, reaching $6.75. About 1.73M shares traded or 862.87% up from the average. Strongbridge Biopharma plc (NASDAQ:SBBP) has declined 15.09% since January 26, 2017 and is downtrending. It has underperformed by 31.79% the S&P500.The move comes after 9 months negative chart setup for the $268.73M company. It was reported on Jan, 26 by Barchart.com. We have $6.14 PT which if reached, will make NASDAQ:SBBP worth $24.19 million less.

Key Technology, Inc., together with its subsidiaries, designs, makes, sells, and services process automation systems integrating electro-optical inspection, sorting, and process systems in the United States and internationally. The company has market cap of $172.67 million. It provides automated inspection systems, including belt-fed sorters, Optyx, Tegra, and Manta that are primarily used in the fresh and frozen fruit, vegetable, and potato products; chute-fed sorters, such as the Taurys, Spyder, Python, and Cayman for sorting nuts, dried and frozen fruits, and vegetables; Veo, an optical sorter for seed corn; VitiSort for red wine grapes; Tobacco Sorter systems used in tobacco threshing and primary processing; and ADR, an automatic defect removal system for use in the potato strip industry. It has a 42.64 P/E ratio. The firm also offers automated inspection equipment for solid dose pharmaceuticals and nutraceuticals through its SYMETIX pharmaceutical product line.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company has market cap of $268.73 million. The firm offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It currently has negative earnings. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly.

Analysts await Strongbridge Biopharma plc (NASDAQ:SBBP) to report earnings on March, 26. They expect $-0.31 EPS, down 24.00% or $0.06 from last year’s $-0.25 per share. After $-0.39 actual EPS reported by Strongbridge Biopharma plc for the previous quarter, Wall Street now forecasts -20.51% EPS growth.

Among 3 analysts covering Strongbridge Biopharma (NASDAQ:SBBP), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Strongbridge Biopharma had 3 analyst reports since November 10, 2015 according to SRatingsIntel. As per Tuesday, November 10, the company rating was initiated by JMP Securities. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, January 25 report. As per Tuesday, November 10, the company rating was initiated by Stifel Nicolaus.

Kokino Llc holds 40.33% of its portfolio in Key Technology, Inc. for 1.22 million shares. Teton Advisors Inc. owns 130,707 shares or 0.23% of their US portfolio. Moreover, Disciplined Growth Investors Inc Mn has 0.09% invested in the company for 222,905 shares. The Virginia-based Thompson Davis & Co. Inc. has invested 0.03% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 60,400 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts